- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Merck to Spin Off Biosimilars Business to Focus on Pembrolizumab
Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.
Merck said Wednesday it is spinning off its biosimilars business into a new company, along with women’s health products and other brands, in order to focus on its oncology drug pembrolizumab (Keytruda).
Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.
Another biosimilar from the partnership, SB8, a proposed bevacizumab biosimilar referencing Avastin, is under review by the FDA; a decision is expected later this year.
In a company release, Merck said the new firm “is well-positioned to be a partner in the commercialization of biosimilars worldwide.” It will be headquartered in New Jersey (as is Merck), with about 10,000 to 11,000 employees, and will have approximately 75% of sales generated from markets outside of the United States. The spun off products are expected to generate 2020 revenue of approximately $6.5 billion within Merck; as an independent company from a 2021 base-year of approximately $6.0 billion to $6.5 billion in revenue, the new firm is expected to achieve low-single-digit revenue growth.
The new firm's chief executive officer (CEO) will be Kevin Ali, who has spent about 30 years within Merck.
“Over the past several years, we have purposefully shifted the focus of our efforts and resources to our best opportunities for growth,” said Kenneth C. Frazier, Merck's chairman and CEO.
Sales of the 3 biosimilars were about $250 million last year; sales of pembrolizumab were $11 billion, according to The Wall Street Journal.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
